TABLE OF CONTENTS 1) Acknowledgement 2 2) Certificate of Authenticity 3 3) Research Objectives 5 4) Executive Summary 6 5) Chapter 1: Economic Analysis 7 6) Chapter 2: Industry Analysis 9
Words: 11741 - Pages: 47
Introduction of Pfizer Pfizer is an American multinational pharmaceutical corporation that headquartered in New York City [Pfizer. Retrieved on April 3, 2010] and with its research headquarters in Groton, Connecticut and United States. It is one of the world's largest pharmaceutical companies by revenues.[Bloomberg Businessweek. 27 March 2012. Retrieved 8 July 2012] Pfizer develops and produces medicines and vaccines for a wide range of medical disciplines that includes immunology, oncology,
Words: 2504 - Pages: 11
9 -3 1 3 -0 1 6 REV: AUGUST 1, 2014 REGINA E. HERZLINGER NATALIE KINDRED Shanghai Pharmaceuticals With 2011 revenues of $8.67 billion, 1 Shanghai Pharmaceuticals (SPH), a vertically integrated Chinese pharmaceutical conglomerate, produced active pharmaceutical ingredients (APIs), chemical and biological drugs, and traditional Chinese medicines (TCMs); distributed its own and other drug makers’ products to hospitals and other customers; and operated a chain of retail pharmacies. The company—essentially
Words: 12061 - Pages: 49
Business Ethics and Legal Issues Student’s Name: Institutional Affiliation: Abstract Antitrust laws are the legislations by state governments aimed regulating the way in which trade and commerce is carried out. This is possible through the prevention of illegitimate price-fixing and monopolies and facilitating fair completion. The net effect that is felt by the consumer is the production of high quality goods and services at prices that are affordable to all. Additionally, the public welfare and
Words: 1950 - Pages: 8
The Pharmaceutical industry in the Global Economy Summer 2005 Larry Davidson* and Gennadiy Greblov Indiana University Kelley School of Business Bloomington, Indiana *Davidson is Professor of Business Economics and Public Policy and Greblov is working towards his MBA degree at the Kelley School of Business Prepared for the Indiana Economic Development Corporation with the support of the Center for International Business Education and Research at the Indiana
Words: 10094 - Pages: 41
manufacture the drug. These drugs are referred to as generic drugs. They do not incur the costs for development or clinical testing and are able produce the drugs for the cost of manufacturing. They may also derive the benefit of patented drugs existing marketing campaign and customer base. With the loss of patent protection the company with the patent will see revenues and profits fall if the drug is in demand. Competitors will manufacture generic versions. One strategy to mitigate the loss pursue
Words: 1098 - Pages: 5
strategies of both firms have taken a divergent direction. Lilly would like to continue to focus on the development of its patented global drugs, through innovation and discovery. On the other hand, Ranbaxy believes that its opportunity lies in offering generic drugs to the local market and increasing its presence abroad. Ranbaxy has signaled an intention to sell its stake in the JV if the opportunity were to arise. External/Industry Analysis The Indian pharmaceutical industry has been known for its
Words: 1871 - Pages: 8
U.S. Congress passed the Waxman-Hatch Act; simplifying the FDA approval process for generic drugs. Manufacturers of generic drugs were now required to show only that their drugs were chemically and biologically equivalent to the original patented version of the drug. And so, an FDA approved generic drug was considered equivalent, in its effect, to a “branded” drug. Waxman-Hatch enabled manufacturers of generic drugs to enter the market more easily, while also greatly reducing their research costs
Words: 793 - Pages: 4
CASE 6-3 “Eli Lilly in India: Rethinking the Joint Venture Strategy” 1. I think Eli Lilly pursued the right strategy joining Ranbaxy Laboratories to enter the Indian market. While companies were using the global market to amortize the huge investments required to produce a new drug, they were hesitant to invest in countries where the intellectual property regime was weak. During the 1990s both companies had a strong reason for the joint venture. Ranbaxy wanted to make its presence globally
Words: 855 - Pages: 4
widely regarded as vampires who exploit the sick and ignore the sufferings of the poor. These criticisms reached a crescendo more than a decade ago at the peak of the HIV plague. When South Africa’s government sought to legalise the import of cheap generic copies of patented AIDS drugs, pharmaceutical companies took it to court. The case earned the nickname “Big Pharma v Nelson Mandela”. It was a low point for the industry, which wisely backed down. Now arguments over drugs pricing are rising again
Words: 778 - Pages: 4
